Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 7
Submit an article Journal homepage
1,218
Views
0
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900) following a single oral dose in healthy male participants

Peter Mutcha KalVista Pharmaceuticals, Salisbury, UKCorrespondence[email protected]
View further author information
,
Mohammad Bashirb Labcorp Drug Development, Madison, WI, USAView further author information
,
Bonnie Jungb Labcorp Drug Development, Madison, WI, USAView further author information
,
Ping Yib Labcorp Drug Development, Madison, WI, USAView further author information
&
Matt Iversonc KalVista Pharmaceuticals, Cambridge, MA, USAView further author information
Pages 707-717 | Received 18 Jul 2022, Accepted 30 Sep 2022, Published online: 17 Oct 2022

References

  • Banday AZ, Kaur A, Jindal AK, Rawat A, Singh S. 2020. An update on the genetics and pathogenesis of hereditary angioedema. Genes Dis. 7(1):75–83.
  • Busse PJ, Christiansen SC. 2020. Hereditary angioedema. N Engl J Med. 382(12):1136–1148.
  • Drouet C, López-Lera A, Ghannam A, López-Trascasa M, Cichon S, Ponard D, Parsopoulou F, Grombirikova H, Freiberger T, Rijavec M, et al. 2022. SERPING1 variants and C1-INH biological function: a close relationship with C1-INH-HAE. Front Allergy. 3:835503.
  • Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP. 2022. Pharmacological suppression of the kallikrein kinin system with KVD900: an orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. Clin Exp Allergy. 52(9):1059–1070.
  • Hop CE, Wang Z, Chen Q, Kwei G. 1998. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci. 87(7):901–903.
  • Kaplan AP. 2014. The bradykinin-forming cascade: a historical perspective. Chem Immunol Allergy. 100:205–213.
  • Kaplan AP, Joseph K. 2014. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 121:41–89.
  • Longhurst H, Cicardi M. 2012. Hereditary angio-oedema. Lancet. 379(9814):474–481.
  • Maetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, et al. 2022. KVD900, an oral on-demand treatment for hereditary angioedema: phase 1 study results. J Allergy Clin Immunol. 149(6):2034–2042.
  • Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, Bowen T, Balle Boysen H, Farkas H, Grumach AS, et al. 2018. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2017 revision and update. Allergy. 73(8):1575–1596.
  • Nicola S, Rolla G, Brussino L. 2019. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs Context. 8:212605.
  • US Food and Drug Administration. 2010. Guidance document: M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals [accessed 2022 May 13]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization.
  • US Food and Drug Administration. 2020. Safety testing of drug metabolites: guidance for industry [accessed 2022 May 13]. https://www.fda.gov/media/72279/download.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.